首页> 外文OA文献 >A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors

【2h】

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors

机译：先进实体肿瘤患者的斯坦利申草（PDR001），抗PD-1抗体，抗PD-1抗体，抗PD-1抗体，抗PD-1抗体的第一阶段1剂量升级研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Aung Naing; Justin F Gainor; Hans Gelderblom; Patrick M Forde; Marcus O Butler; Chia-Chi Lin; Sunil Sharma; Maria Ochoa de Olza; Andrea Varga; Matthew Taylor; Jan H M Schellens; Hongqian Wu; Haiying Sun; Antonio P Silva; Jason Faris; Jennifer Mataraza; Scott Cameron; Todd M Bauer;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 抗PD-1抗体特瑞普利单抗治疗难治性恶性实体瘤的I期研究 [J] . 魏小丽, 骆卉妍, 王峰, 癌症（英文版） . 2021,第010期
2. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors [J] . Aung Naing, Justin F Gainor, Hans Gelderblom, Journal for ImmunoTherapy of Cancer . 2020,第1期

机译：先进实体肿瘤患者的斯坦利申草（PDR001），抗PD-1抗体，抗PD-1抗体，抗PD-1抗体，抗PD-1抗体的第一阶段1剂量升级研究
3. THE RECOMMENDED PHASE II DOSE SELECTION FOR SPARTALIZUMAB (PDR001), AN ANTI-PD-1 ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS. [J] . Sun H., Sy S., Xu J., Clinical Pharmacology and Therapeutics . 2019,第Suppla1期

机译：患有先进实体瘤的患者的Spartalizumab（PDR001）的推荐期II剂量选择，抗PD-1抗体，抗PD-1抗体。
4. THE RECOMMENDED PHASE II DOSE SELECTION FOR SPARTALIZUMAB (PDR001), AN ANTI-PD-1 ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS. [J] . Sun H., Sy S., Xu J., Clinical Pharmacology and Therapeutics . 2019,第Suppla1期

机译：患有先进实体瘤的患者的Spartalizumab（PDR001）的推荐期II剂量选择，抗PD-1抗体，抗PD-1抗体。
5. Phase I Clinical Trial with Her-2 B-Cell Chimeric and MultiEpitope Based Peptide Vaccines in Patients with Metastatic and/or Recurrent Solid Tumors [C] . Pravin T.P. Kaumaya, Kevin Chu Foy, Joan Garrett American Peptide Symposium . 2009

机译：患者临床试验与患有转移和/或复发性固体瘤的患者的HER-2 B细胞嵌合和多型肽疫苗
6. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
7. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001) an anti–PD-1 antibody in patients with advanced solid tumors [O] . Aung Naing, Justin F Gainor, Hans Gelderblom, 2020

机译：spartalizumab（PDR001）（抗PD-1抗体）在人类晚期实体瘤中的首次人类1期剂量递增研究
8. A Phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors [O] . Angevin, Eric E., Tabernero, Josep, Elez, Elena E., 2014

机译：Siltuximab（一种抗白介素6单克隆抗体）在晚期实体瘤患者中的I / II期，多剂量，剂量递增研究

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors

著录项

引文网络

相似文献

相关主题

期刊订阅